ARIA: Real-world utilization and outcomes with dacomitinib first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi center chart review (A7471067)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/44544
• EU PAS number:
  EUPAS44543
• Study ID:
  44544
• Official title and acronym:
  ARIA: Real-world utilization and outcomes with dacomitinib first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer among Asian patients – A multi center chart review (A7471067)
• DARWIN EU® study:
  No
• Study countries:
  China

  India

  Malaysia
• Study description:
  This is a longitudinal, multi-center cohort study with mixed prospective and retrospective data collection. Data will be collected from eligible adults with EGFR mutation-positive advanced NSCLC treated with dacomitinib as first-line therapy from the date of advanced NSCLC diagnosis to the date of death, lost to follow-up, withdrawal of consent or end of study, whichever occurs first.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Pfizer

IQVIA

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 20/03/2020

Actual: 20/03/2020

Study start date

Planned: 05/05/2021

Actual: 11/06/2021

Date of final study report

Planned: 31/10/2024

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Pfizer

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable